4//SEC Filing
5AM Ventures IV, L.P. 4
Accession 0001567619-19-012279
CIK 0001676725other
Filed
May 27, 8:00 PM ET
Accepted
May 28, 8:40 PM ET
Size
32.9 KB
Accession
0001567619-19-012279
Insider Transaction Report
Form 4
5AM Ventures IV, L.P.
10% Owner
Transactions
- Purchase
Common Stock
2019-05-28$10.00/sh+10,000$100,000→ 118,521 total(indirect: See footnote) - Conversion
Series A Preferred Stock
2019-05-28−1,721,898→ 0 total(indirect: See footnote)→ Common Stock (1,721,898 underlying) - Conversion
Series B Preferred Stock
2019-05-28−578,447→ 0 total(indirect: See footnote)→ Common Stock (578,447 underlying) - Conversion
Common Stock
2019-05-28+578,447→ 2,604,545 total(indirect: See footnote) - Conversion
Common Stock
2019-05-28+24,101→ 108,521 total(indirect: See footnote) - Conversion
Series A Preferred Stock
2019-05-28−71,745→ 0 total(indirect: See footnote)→ Common Stock (71,745 underlying) - Conversion
Common Stock
2019-05-28+1,721,898→ 2,026,098 total(indirect: See footnote) - Conversion
Common Stock
2019-05-28+71,745→ 84,420 total(indirect: See footnote) - Purchase
Common Stock
2019-05-28$10.00/sh+240,000$2,400,000→ 2,844,545 total(indirect: See footnote) - Purchase
Common Stock
2019-05-28$10.00/sh+500,000$5,000,000→ 500,000 total(indirect: See footnote) - Conversion
Series B Preferred Stock
2019-05-28−24,101→ 0 total(indirect: See footnote)→ Common Stock (24,101 underlying)
Footnotes (6)
- [F1]Reflects a 1-for-10.2564 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement.
- [F2]Each share of Series A Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.
- [F3]The shares are held by 5AM Ventures IV, L.P. ("Ventures IV"). 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Ventures IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein.
- [F4]Each share of Series B Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.
- [F5]The shares are held by 5AM Co-Investors IV, L.P. ("Co-Investors IV"). Partners IV is the sole general partner of Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Co-Investors IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein.
- [F6]The shares are held by 5AM Opportunities I, L.P. ("Opportunities I"). 5AM Opportunities I (GP), LLC ("Opportunities I GP") is the sole general partner of Opportunities I. Kush Parmar and Andrew J. Schwab are the managing members of Opportunities I GP, and have shared voting and investment power over the shares beneficially owned by Opportunities I. Each of Opportunities I GP and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein.
Documents
Issuer
IDEAYA Biosciences, Inc.
CIK 0001676725
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001589315
Filing Metadata
- Form type
- 4
- Filed
- May 27, 8:00 PM ET
- Accepted
- May 28, 8:40 PM ET
- Size
- 32.9 KB